Kepro CTC 20% WSP

Indications

• Bacterial infections
• Respiratory tract infections
• Urinary tract infections
• Acne
• Chlamydia infections
• Mycoplasma pneumonia

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Refer to the BNF for specific dosing information.

Mechanism of action

Chlortetracycline exerts its antibacterial effect by binding to the 30S ribosomal subunit of bacteria, inhibiting protein synthesis. This action prevents the addition of amino acids to the growing polypeptide chain, ultimately leading to cell death in susceptible organisms. It is effective against a variety of organisms, including both aerobic and anaerobic bacteria.

Pharmacodynamics

The pharmacodynamics of chlortetracycline involves its ability to inhibit bacterial protein synthesis, which is crucial for bacterial growth and reproduction. The drug's effectiveness is dependent on the concentration of the drug at the site of infection and the susceptibility of the bacteria. Bacteriostatic in nature, chlortetracycline stops bacteria from multiplying rather than killing them outright.

Pharmacokinetics

Chlortetracycline is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1 to 2 hours after oral administration. It is widely distributed throughout the body, including into tissues and body fluids. The drug can be excreted in urine, and its half-life varies from 6 to 12 hours, depending on the individual’s renal function. Biliary excretion also occurs.

Contra-indications

• Hypersensitivity to chlortetracycline or any component of the formulation
• Porphyria
• Renal impairment

Adverse effects

• Gastrointestinal disturbances (nausea, vomiting, diarrhea)
• Photosensitivity
• Skin rashes
• Esophageal irritation
• Hepatotoxicity
• Superinfection (due to prolonged use)

Interactions

• Antacids containing aluminum, calcium, or magnesium may reduce absorption of chlortetracycline
• Iron supplements can interfere with absorption
• Oral contraceptives may have reduced efficacy when taken with chlortetracycline
• Warfarin may have increased anticoagulant effect

Precautions

• Use with caution in patients with liver or renal impairment
• Monitor for signs of superinfection
• Avoid prolonged exposure to sunlight or UV light
• Consider potential effects on developing teeth in children

Pregnancy

Chlortetracycline is generally not recommended during pregnancy due to potential harm to the developing fetus, particularly effects on tooth development.

Breast-feeding

Chlortetracycline is excreted in breast milk and may affect the infant; use with caution.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

• Oral tablets
• Topical ointments
• Liquid formulations

Indications

• Monitoring respiratory function
• Assessment of metabolic status
• Management of respiratory acidosis
• Management of respiratory alkalosis

Dosage

Children: Dosing for interventions related to carbon dioxide levels in pediatric patients should be guided by clinical protocols and the BNF for Children.

Adults: Dosing for interventions related to carbon dioxide levels is typically based on clinical assessment and individual patient needs. Refer to clinical guidelines for specific scenarios.

Mechanism of action

Carbon dioxide acts primarily as a signaling molecule in the body, influencing respiratory drive and blood pH. It is produced during cellular respiration and is a critical component of the bicarbonate buffering system, which helps maintain acid-base homeostasis. Elevated levels of CO2 in the blood stimulate ventilation in the lungs, increasing the rate of gas exchange and facilitating the removal of excess CO2.

Pharmacodynamics

The pharmacodynamic effects of dioxides, particularly carbon dioxide, are closely related to its concentration in the blood. As CO2 levels increase, it leads to respiratory acidosis, which can stimulate the respiratory centers in the brain to increase ventilation. Conversely, low levels of CO2 can cause respiratory alkalosis, potentially leading to decreased respiratory drive. CO2 also plays a role in vasodilation and can affect blood flow and pressure through its influence on smooth muscle tone.

Pharmacokinetics

Carbon dioxide is produced endogenously during metabolic processes and is transported in the bloodstream primarily in three forms: dissolved in plasma, as bicarbonate ions (HCO3-), and bound to hemoglobin. The half-life of CO2 in the bloodstream is very short due to its rapid exchange with alveolar gas in the lungs. The elimination of CO2 occurs through exhalation, making it a dynamic component of respiratory physiology.

Pregnancy

Data on the effects of dioxide during pregnancy are limited. Caution is advised due to potential risks associated with exposure.

Breast-feeding

Limited data are available regarding the excretion of dioxide in human milk. Caution is recommended.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Indications

• Lactose intolerance
• As a filler or excipient in pharmaceutical formulations

Dosage

Children: Refer to the BNF for Children for specific dosing information based on age and clinical context.

Adults: Refer to the BNF for specific dosing information based on clinical context.

Mechanism of action

Lactose is metabolized in the intestine by the enzyme lactase into its constituent monosaccharides, glucose and galactose. In individuals with lactase deficiency, unabsorbed lactose passes into the colon, where it is fermented by bacteria, leading to gas production and osmotic effects that contribute to diarrhea.

Pharmacodynamics

The pharmacodynamics of lactose are primarily related to its effects on gastrointestinal function. In healthy individuals, lactose is effectively broken down into glucose and galactose, which are absorbed and utilized for energy. In individuals with lactose intolerance, the unabsorbed lactose can cause osmotic diarrhea and colonic fermentation, leading to discomfort and symptoms associated with lactose intolerance.

Pharmacokinetics

Lactose is not absorbed in the gastrointestinal tract until it is hydrolyzed into glucose and galactose by lactase. The absorption of glucose and galactose occurs in the small intestine. The half-life is not applicable as lactose is not typically administered as a medication but is rather ingested as a natural component of food. Its metabolism primarily occurs in the intestine.

Adverse effects

• Bloating
• Diarrhea
• Abdominal pain
• Flatulence

Precautions

• Use with caution in patients with lactose intolerance.
• Consider potential for gastrointestinal upset in sensitive individuals.

Pregnancy

Lactose is generally considered safe for use during pregnancy. However, consult a healthcare professional for individual advice.

Breast-feeding

Lactose is safe to use while breastfeeding, as it is a natural sugar present in breast milk.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Powder
• Granules
• Tablets
• Syrup

Indications

• Bone health
• Support for connective tissue integrity
• Potential role in osteoporosis management

Dosage

Children: Refer to specific product guidelines and BNF for Children recommendations for appropriate dosing.

Adults: Refer to specific product guidelines and BNF recommendations for appropriate dosing.

Mechanism of action

Silicon is thought to be involved in the formation of collagen, an essential protein in connective tissues, and may enhance bone mineralization. It is believed to influence the activity of various enzymes involved in the synthesis of glycosaminoglycans and collagen, thereby supporting the structural integrity of bones and cartilage.

Pharmacodynamics

Silicon plays a role in bone density and the health of connective tissues. It may contribute to the prevention of osteoporosis and support joint health by promoting collagen synthesis. The pharmacodynamic effects are generally related to its role in bone mineralization and the maintenance of connective tissue.

Pharmacokinetics

Silicon is not typically measured or monitored in clinical practice. It is absorbed from the gastrointestinal tract and is mainly found in the bone, connective tissues, and skin. The exact pharmacokinetics of silicon, including its half-life and elimination pathways, are not well defined due to limited clinical studies.

Pregnancy

There is insufficient data on the safety of silicium during pregnancy; consult healthcare providers for guidance.

Breast-feeding

Limited data is available regarding the safety of silicium during breastfeeding; consult healthcare providers for personalized advice.

Storage

Store in a cool, dry place away from direct sunlight.